Nyxoah SA
NYXH4.650USD
+0.060+1.31%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
174.58MMarket Cap
LossP/E TTM
More Details of Nyxoah SA Company
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Nyxoah SA Info
Ticker SymbolNYXH
Company nameNyxoah SA
IPO dateSep 18, 2020
CEOTaelman (Olivier)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endSep 18
AddressRue Edouard Belin 12
CityMONT-SAINT-GUIBERT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryBelgium
Postal code1435
Phone3226121755
Websitehttps://www.nyxoah.com/
Ticker SymbolNYXH
IPO dateSep 18, 2020
CEOTaelman (Olivier)
Company Executives of Nyxoah SA
Name
Name/Position
Position
Shareholding
Change
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.31M
+70000.00%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Juergen Hambrecht, Ph.D.
Dr. Juergen Hambrecht, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Rita F. Johnson-Mills
Ms. Rita F. Johnson-Mills
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pierre Gianello, M.D.
Dr. Pierre Gianello, M.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Christoph Eigenmann
Mr. Christoph Eigenmann
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Francis Kim
Mr. Francis Kim
Chief Regulatory and Quality Officer
Chief Regulatory and Quality Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.31M
+70000.00%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Juergen Hambrecht, Ph.D.
Dr. Juergen Hambrecht, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Rita F. Johnson-Mills
Ms. Rita F. Johnson-Mills
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pierre Gianello, M.D.
Dr. Pierre Gianello, M.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Jan 18
Updated: Sun, Jan 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cochlear Limited
13.59%
Taub (Robert)
10.02%
Monden (Anneliese)
6.83%
Gilde Healthcare Partners B.V.
6.83%
ResMed Inc
4.02%
Other
58.72%
Shareholders
Shareholders
Proportion
Cochlear Limited
13.59%
Taub (Robert)
10.02%
Monden (Anneliese)
6.83%
Gilde Healthcare Partners B.V.
6.83%
ResMed Inc
4.02%
Other
58.72%
Shareholder Types
Shareholders
Proportion
Individual Investor
19.98%
Corporation
17.61%
Investment Advisor
8.68%
Venture Capital
7.02%
Investment Advisor/Hedge Fund
5.74%
Hedge Fund
0.63%
Research Firm
0.17%
Other
40.19%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
80
9.57M
22.23%
+68.26K
2025Q3
74
8.21M
21.94%
-2.04M
2025Q2
69
25.16M
67.22%
-3.01M
2025Q1
70
26.40M
70.53%
-2.65M
2024Q4
73
25.60M
68.47%
-1.01M
2024Q3
72
23.51M
71.46%
-828.78K
2024Q2
72
23.54M
72.39%
-1.11M
2024Q1
64
20.89M
72.68%
+374.51K
2023Q4
59
21.08M
73.36%
-418.05K
2023Q3
66
19.86M
69.10%
-2.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cochlear Limited
5.85M
13.59%
+215.96K
+3.84%
Nov 20, 2025
Taub (Robert)
4.31M
10.02%
+70.00K
+1.65%
Dec 01, 2025
Monden (Anneliese)
2.94M
6.83%
--
--
Dec 31, 2024
Gilde Healthcare Partners B.V.
2.94M
6.83%
--
--
Dec 31, 2024
ResMed Inc
1.73M
4.02%
--
--
Dec 31, 2024
BNP Paribas Asset Management Belgium S.A.
732.78K
1.7%
--
--
Nov 30, 2025
Hambrecht (Jürgen)
1.34M
3.12%
--
--
Dec 31, 2024
Vestal Point Capital, LP
1.11M
2.57%
-294.59K
-21.01%
Sep 30, 2025
Heights Capital Management, Inc.
831.43K
1.93%
+831.43K
--
Dec 18, 2025
BlackRock Financial Management, Inc.
647.21K
1.5%
-36.44K
-5.33%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Health Innovation Active ETF
0.09%
Avantis International Equity ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
SPDR Portfolio Europe ETF
0%
DFA Dimensional International Small Cap ETF
0%
Avantis International Small Cap Equity ETF
0%
iShares Health Innovation Active ETF
Proportion0.09%
Avantis International Equity ETF
Proportion0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
SPDR Portfolio Europe ETF
Proportion0%
DFA Dimensional International Small Cap ETF
Proportion0%
Avantis International Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
